B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2025

Description

B-cell maturation antigen (BCMA) targeted therapies are a class of treatments designed to specifically target BCMA, a protein found on the surface of mature B-cells and plasma cells. BCMA, a member of the tumor necrosis factor (TNF) receptor superfamily, plays an essential role in B-cell development, survival, and differentiation into plasma cells. These therapies represent a significant advancement in treating multiple myeloma, providing effective options for patients with relapsed or refractory disease.

The main types of products in BCMA-targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. ADCs are targeted treatments that attach a cancer-specific antibody to a cytotoxic drug, allowing for the precise destruction of cancer cells while minimizing damage to healthy tissue. The primary indications for these therapies include acute lymphoblastic leukemia and multiple myeloma. These treatments are used by various end users, such as hospitals, specialty clinics, and home care settings.

The B-cell maturation antigen (BCMA) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides B-cell maturation antigen (BCMA) targeted therapies market statistics, including the B-cell maturation antigen (BCMA) targeted therapies industry global market size, regional shares, competitors with the B-cell maturation antigen (BCMA) targeted therapies market share, detailed B-cell maturation antigen (BCMA) targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the B-cell maturation antigen (BCMA) targeted therapies industry. This B-cell maturation antigen (BCMA) targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The B-cell maturation antigen (BCMA) targeted therapies market size has grown exponentially in recent years. It will grow from $12.17 billion in 2024 to $15.21 billion in 2025 at a compound annual growth rate (CAGR) of 25.0%. The growth during the historical period can be attributed to an increasing focus on hematologic malignancies, rising investments in oncology research, a growing demand for personalized medicine, higher adoption of CAR-T cell therapies, and rising healthcare expenditure.

The B-cell maturation antigen (BCMA) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $36.66 billion in 2029 at a compound annual growth rate (CAGR) of 24.6%. The expected growth in the forecast period is driven by a continued focus on cancer research, a shift toward targeting specific molecular markers, the rising incidence of cancers, a surge in biotech investments, and the expanding use of cell and gene therapies. Key trends in the forecast period include innovations such as CRISPR technology, advancements in gene-editing technologies, the development of next-generation CAR-T cell therapies, progress in targeted antibody-drug conjugates, and the creation of off-the-shelf treatments.

The growing prevalence of multiple myeloma is anticipated to drive the expansion of the B-cell maturation antigen (BCMA) targeted therapies market. Multiple myeloma, a cancer that mainly impacts plasma cells-vital components of the immune system responsible for antibody production-is becoming more common due to factors such as an aging global population, enhanced diagnostic tools, and varying levels of healthcare access. BCMA-targeted therapies are essential for treating this condition, as they focus on eliminating malignant plasma cells expressing BCMA, offering a more precise and effective treatment option. For example, the American Cancer Society projected that in 2024, the United States would see approximately 35,780 new multiple myeloma cases, including 19,520 in men and 16,260 in women. The expected death toll is around 12,540, with 7,020 male deaths and 5,520 female deaths. As a result, the increasing incidence of this cancer is fueling growth in the BCMA-targeted therapies market.

Leading companies in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing cutting-edge treatments such as CAR-T cell therapy to improve the effectiveness and accuracy of targeting cancer cells. CAR-T cell therapy is an immunotherapy that involves altering a patient's T cells to express chimeric antigen receptors (CARs), enabling them to specifically attack and eliminate cancer cells. For example, in April 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma who have undergone at least one previous line of treatment and are resistant to lenalidomide.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for around $1.2 billion. This acquisition is aimed at strengthening AstraZeneca's cell therapy portfolio by incorporating Gracell's FasTCAR-enabled GC012F therapy, which targets cancer and autoimmune diseases, addressing critical unmet medical needs. Gracell Biotechnologies, based in China, specializes in developing BCMA therapies for multiple myeloma and B-cell malignancies.

Major players in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in B-cell maturation antigen (BCMA) targeted therapies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on b-cell maturation antigen (bcma) targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for b-cell maturation antigen (bcma) targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The b-cell maturation antigen (bcma) targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Antibody Drug Conjugates; Chimeric Antigen Receptor T (CAR-T)-Cell Therapy; Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia; Multiple Myeloma
3) By End User: Hospitals; Specialty Clinics; Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates); Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous); Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies; BCMA x CD28 Bispecific Antibodies
Companies Mentioned: Bristol Myers Squibb Company; Novartis; GlaxoSmithKline (GSK); Takeda Pharmaceutical Company Limited; Amgen Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33648

1. Executive Summary

2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Characteristics

3. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends And Strategies

4. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Analysis And Strategic Analysis Framework

5.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate Analysis
5.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Total Addressable Market (TAM)

6. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segmentation

6.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibody Drug Conjugates
Chimeric Antigen Receptor T (CAR-T)-Cell Therapy
Bispecific Antibodies
6.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Lymphoblastic Leukemia
Multiple Myeloma
6.3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Home Care Settings
6.4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Antibody Drug Conjugates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BCMA-Targeted ADCs (Antibody-Drug Conjugates)
Linker-Payload Technology-Based BCMA ADCs
6.5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor T (CAR-T)-Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BCMA CAR-T Cells (Autologous)
Allogeneic BCMA CAR-T Cells
6.6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BCMA x CD3 Bispecific Antibodies
BCMA x CD28 Bispecific Antibodies

7. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Regional And Country Analysis

7.1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

8.1. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

9.1. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
9.2. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

10.1. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

11.1. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
11.2. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

12.1. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

13.1. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

14.1. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
14.2. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

15.1. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
15.2. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

16.1. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

17.1. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

18.1. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

19.1. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

20.1. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

21.1. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
21.2. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

22.1. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

23.1. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
23.2. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

24.1. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
24.2. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

25.1. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
25.2. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

26.1. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
26.2. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

27.1. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

28.1. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
28.2. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

29.1. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
29.2. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape And Company Profiles

30.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Landscape
30.2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Company Profiles
- 30.2.1. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. GlaxoSmithKline (GSK) Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis

31. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Other Major And Innovative Companies

31.1. Regeneron Pharmaceuticals
31.2. Beigene
31.3. Arcellx Inc
31.4. Poseida Therapeutics
31.5. Legend Biotech Corporation
31.6. Cartesian Therapeutics
31.7. Juno Therapeutics
31.8. Sutro Biopharma Inc
31.9. CARsgen Therapeutics
31.10. Precision BioSciences
31.11. Eureka Therapeutics Inc
31.12. Cellectis
31.13. Teneobio Inc.
31.14. Janssen Pharmaceuticals Companies
31.15. Allogene Therapeutics

32. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

34. Recent Developments In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market

35. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market High Potential Countries, Segments and Strategies

35.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Countries Offering Most New Opportunities
35.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Segments Offering Most New Opportunities
35.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer